18 results about "Oral administration" patented technology

The invention provides novel curcuminoid formulations which have improved aqueous solubility and bioavailability when compared to known curcuminoid dosage forms. Formulations of the invention exhibit an enhanced intestinal absorption of curcuminoids, a slower curcuminoid metabolism and a reduced rate of systemic curcuminoid elimination. Additionally, upon administration in vivo, the formulations described and claimed herein produce a high, sustained level of the curcuminoid metabolite tetrahydrocurcumin. For example, at about eight to about ten hours after oral administration to a human, tetrahydrocurcumin plasma levels of between about 50 ng/mL to about 175 ng/mL are detectable, even when that metabolite is absent from the administered formulation. Novel processes for making curcuminoid formulations which have improved aqueous solubility and oral bioavailability, and methods of treating a wide variety of inflammatory, immune and neurogenerative disorders and cancers, are also provided.

The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt. % of a granulate; 5-50 wt. % of lactose; and 0-30 wt. % of other tablet excipients; wherein the granulate contains: a.2-15 wt. % of cannabidiol; b.2-30 wt. % of sucrose fatty acid mono-ester; c.30-96 wt. % of lactose; and d.0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

The invention provides a fotemustine solid lipid nanoparticle for injection and oral administration. The nanoparticle is characterized in that a lipid material and an emulsifier are used to encapsulate the fotemustine to prepare the fotemustine solid lipid nanoparticle with small particle diameter, high encapsulation rate, good stability and low toxicity. The prepared fotemustine solid lipid nanoparticle improves the solubility and the stability of the fotemustine, reduces vascular stimulation of the fotemustine, and prolongs the circulating time of the medicament in blood, thereby improving the curative effect of medicaments, and ensuring that preparations made of the solid lipid nanoparticle have the characteristics of low toxicity, low fotemustine solid lipid nanoparticle with low stimulation and high efficiency. The invention also relates to a method for preparing the fotemustine solid lipid nanoparticle, which has simple preparation process and low cost, and is applicable to industrial production.

The invention discloses a traditional Chinese medicinal composition for treating hepatitis and a preparation method thereof. The traditional Chinese medicinal composition for treating the hepatitis is prepared from the following raw materials: pseudo-ginseng root, golden thread, baical skullcap root, amur corktree bark, rhubarb, spreading hedyotis herb, snake gall, borneol, calculus bovis factitius, aritificial musk, curcuma aromatica and red yeast. The traditional Chinese medicinal composition for treating the hepatitis can be prepared into multiple common formulations for oral administration. The traditional Chinese medicinal preparation treats the hepatitis by clearing heat, detoxicating, removing blood stasis, eliminating stagnation, invigorating blood circulation, dissolving stasis, detoxicating and normalizing gallbladder, has the obvious effects of improving liver function and inhibiting liver injury and hepatitis virus, addresses both symptoms and root causes, requires a short treatment period, realizes a low relapse rate, and has the obvious pharmacological action of protecting the liver and reducing transaminase and serum bilirubin.

Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.

In various embodiments, the present disclosure pertains to a composition composed of chlophedianol and menthol, or method of use thereof, having a form of a chewable composition, a chewable gummy, a chewable tablet, a chewable candy, a soft chewable, a hard chewable, a tablet, a capsule, a quick dissolving tablet or capsule, a lozenge, an orally disintegrating tablet, and a liquid composition. In some embodiments, the composition is formulated to alleviate respiratory tract infection symptoms, symptoms cause by allergies, symptoms cause by the common cold, symptoms cause by acute bronchitis, symptoms cause by pneumonia, symptoms cause by pertussis, symptoms cause by influenza, symptoms cause by tuberculosis, post-infectious cough symptoms, dry cough symptoms, productive cough symptoms, non-productive cough symptoms, or coughing and coughing-related symptoms selected from the group consisting of throat soreness, muscle strains or soreness in the abdomen or throat, throat irritation, and lung irritation, or combinations thereof.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).

The invention discloses a cough mixture capable of being drunk by old people for a long time, relates to the field of traditional Chinese medicines and aims to provide the cough mixture capable of being drunk by old people for a long time. In order to realize the purpose, the cough mixture mainly is prepared from 4-7 parts of radix angelicae, 4-8 parts of honey, 16-23 parts of licorice root, 8-11 parts of radix astragali, 6-16 parts of fiveleaf gynostemma herb, 4-6 parts of fructus forsythiae, 4-7 parts of herba ephedrae, 7-14 parts of flos jasmine, 3-9 parts of folium mori, 22-29 parts of rhizoma zingiberis recens and 7-16 parts of pine nut. Water is added into the ingredients for decocting for multiple hours, juice is taken out for refrigeration, a proper quantity of juice is taken for oral administration if required, and cough is alleviated if a user insists for a long time. In conclusion, the cough mixture has the beneficial effect that the cough of old people can be alleviated after the cough mixture is taken for a long time.

The invention discloses a Chinese and western medicine composition. The composition is prepared from the following components in parts by weight: 0.5 to 2 parts of metformin preparation containing 0.5 g of medicinal components, 5 to 20 parts of radix scutellariae, 5 to 20 parts of radix paeoniae alba, 5 to 15 parts of honey-fried licorice root and 5 to 15 parts of fructus ziziphi jujubae. The invention further provides a method for preparing the traditional Chinese medicine compound through decoction extraction and then combining the traditional Chinese medicine compound with the metformin preparation, application of the Chinese and western medicine composition in preparation of medicine for treating type 2 diabetes mellitus. The invention has the advantages that the blood glucose reducing effect of the Chinese and western medicine composition is improved by taking the common target of intestinal flora as an entry point and aiming at patients who are ineffective in reducing blood glucose by oral administration of metformin clinically.

The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.

The invention relates to a traditional Chinese medicine preparation, in particular to an oral administration traditional Chinese medicine for treating prostate swelling hematuria. The medicine is made from the following raw materials in portion by weight: 13 to15 g of raw achyranthes and Japanese thistle herb each, 9 to12 g of limonium bicolor and big bark each, and 25 to30 g of ice stone. The traditional Chinese medicine preparation is characterized in low cost, easy preparation, few toxic and side effects and significant efficacy.